Notice of Interim Results

RNS Number : 2027O
Oxford Biomedica PLC
24 June 2010






Oxford, UK - 24 June 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announces today that it will be releasing its interim results for the six months ended 30 June 2010 on Tuesday 24 August 2010.

An analyst briefing will be held at 9:30am on Tuesday 24 August 2010 at the offices of M:Communications, CityPoint, 1 Ropemaker Street, London, EC2Y 9AW.

Simultaneously to the analyst briefing at 9:30am, there will be a live audio webcast of the presentation. To connect to the webcast facility, please go to the Company's website: approximately 10 minutes (9:20am) before the start of the briefing. This will also be available for replay shortly after the presentation.


For further information, please contact:

Oxford BioMedica plc:

John Dawson, Chief Executive Officer


Tel: +44 (0)1865 783 000


Media/Financial Enquiries:

Emma Thompson/ Rob Newman/ Ben Simons



Tel: +44 (0)20 7920 2345



US Enquiries:

Thomas Fechtner

The Trout Group LLC


Tel: +1 (646) 378 2900


Notes to editors

1. Oxford BioMedica®

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at



This information is provided by RNS
The company news service from the London Stock Exchange